Nocutil (Desmopressin Acetate)

Desmopressin acetate is a synthetic analogue of vasopressin that selectively activates V2 receptors in the kidney’s collecting ducts. This activation raises cyclic AMP, causing aquaporin‑2 channels to move to the cell surface and reabsorb water, concentrating urine. In blood vessels, it stimulates release of von Willebrand factor and factor VIII, enhancing haemostasis.

The dose of Nocutil is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function, and response to therapy. Dosage adjustments may be required for children, patients with impaired kidney function, or those at risk of hyponatremia. The prescriber sets the exact regimen.

Safety data for desmopressin acetate in pregnancy and lactation are limited. The drug is classified as a prescription medication, and its use should only be considered when the potential benefit justifies any possible risk to the fetus or infant. Clinicians should discuss individual circumstances with the patient.

To order Nocutil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Nocutil (desmopressin acetate) is a selective V2‑receptor agonist, offering a longer duration of action and a lower risk of vasoconstriction compared with older antidiuretic agents such as vasopressin. It is generally preferred for central diabetes insipidus and nocturnal enuresis because of its oral formulation and targeted mechanism, while other agents may require injection or have broader receptor activity.

Nocutil tablets should be stored at ambient temperature, below 25 °C, in their original blister pack or container. Protect them from moisture, direct sunlight, and excessive heat. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Nocutil is taken orally as a tablet. The tablet is swallowed whole with water and should be taken at the time and frequency prescribed by the healthcare professional. Patients are usually advised to follow specific fluid‑restriction guidelines to reduce the risk of hyponatremia, especially when used for antidiuretic purposes.

The most serious risks include severe hyponatremia that can lead to seizures or cerebral edema, water intoxication, and rare thromboembolic events. Patients should be monitored closely for signs of electrolyte imbalance, sudden changes in mental status, or unexpected clotting complications, and treatment should be stopped immediately if these occur.

Nocutil should be avoided in patients with known hypersensitivity to desmopressin or any tablet excipients, uncontrolled hyponatremia, severe renal impairment, or in those taking other potent antidiuretic agents without close monitoring. Caution is also advised for individuals with a history of epilepsy, uncontrolled hypertension, or active thromboembolic disease.